Yesterdays gainers are quickly forgotten, up 170% on the 4/22/19 and loses drops 50% on 4/23/19 on news of new offering. Despite this a great opportunity may still exist in the name, tomorrow there is still scheduled call to announce developments in FDA approval and possible positive results from its new lung cancer drug.